Blog
ImmunoMet Therapeutics Presents Updated Clinical Data from Phase 1b Study of Lixumistat in Pancreatic Cancer at ASCO-GI Meeting
[#item_full_content]HOUSTON–(BUSINESS WIRE)–ImmunoMet Therapeutics, Inc., (“ImmunoMet”, or the “Company”), a clinical stage biotechnology company committed to giving…
[#item_full_content]
[#item_full_content]